13F Holdings
中文EN

VVOS Vivos Therapeutics, Inc.

Surgical & Medical Instruments & Apparatus · Nasdaq · SEC CIK 1716166 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY18.6%
TTM net income YoY-28.6%
TTM EPS YoY23.7%
Revenue 3-yr CAGR12.3%
Net income 3-yr CAGR—

Margins

Gross margin60.0%
Operating margin-105.8%
Net margin-107.2%
FCF margin-88.5%
EBITDA margin-96.2%

Returns

ROE-899.5%
ROA-90.7%
ROIC (approx.)-283.8%
Asset turnover0.85x

Leverage & solvency

Liabilities / assets90.5%
Debt / equity0.77x
Current ratio0.22x
Interest coverage-6.03x

Cash quality & payout

Operating cash flow / net income0.73x
Accruals ratio-24.1%
Payout ratio—
Capex / revenue9.9%

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item FY20252025-12-31FY20242024-12-31FY20232023-12-31FY20222022-12-31FY20212021-12-31
Income statement
Revenue$17.44M$15.03M$13.80M$16.02M$16.89M
Cost of revenue$6.90M$6.01M$5.53M$200,000$400,000
Gross profit$10.54M$9.02M$8.27M$10.02M$12.60M
R&D expense$100,000$100,000$100,000$200,000$200,000
SG&A expense$27.73M$17.88M$22.48M$29.04M$25.79M
Operating income-$19.89M-$11.17M-$17.30M-$25.03M-$20.38M
Interest expense$1.40M———$14,000
Pretax income-$21.23M-$11.14M-$13.58M-$23.84M-$20.29M
Net income-$21.17M-$11.14M-$13.58M-$23.84M-$20.29M
EBITDA-$18.59M-$10.59M-$16.68M-$24.36M-$19.65M
EPS (basic)-2.07-2.22-11.14-25.90-0.96
EPS (diluted)-2.07-2.22-11.14-25.90-0.96
Weighted avg. shares (diluted)10.27M5.02M1.22M920,59221.23M
Balance sheet
Cash & equivalents$2.03M$6.26M$1.64M$3.52M$24.03M
Receivables$1.58M$430,000$202,000$457,000$1.20M
Current assets$4.38M$7.47M$2.46M$5.42M$27.32M
PP&E, net$3.76M$3.31M$3.31M$3.08M$2.83M
Goodwill$8.57M$2.84M$2.84M$2.84M$2.84M
Intangibles$4.04M$409,000$420,000$302,000$341,000
Total assets$25.15M$15.28M$10.73M$13.72M$33.69M
Current liabilities$18.08M$4.98M$7.29M$6.81M$7.51M
Short-term debt$8.35M———$1.26M
Long-term debt$469,000$1.20M$1.20M—$1.26M
Total debt$8.82M$1.20M$1.20M—$2.53M
Total liabilities$26.70M$7.33M$10.32M$8.92M$8.15M
Shareholders' equity-$1.49M$7.95M$411,000$4.80M$25.54M
Net debt$6.79M-$5.06M-$443,000—-$21.50M
Shares outstanding9.29M5.89M1.83M920,59223.01M
Cash flow statement
Operating cash flow-$15.26M-$12.69M-$11.95M-$19.59M-$15.73M
Capital expenditure$2.34M$568,000$803,000$924,000$2.40M
Free cash flow-$17.60M-$13.26M-$12.75M-$20.51M-$18.13M
Investing cash flow-$7.53M-$568,000-$853,000-$924,000-$2.61M
Financing cash flow$18.56M$17.88M$10.92M—$24.17M
Depreciation & amortization$1.31M$581,000$621,000$669,000$733,000
Stock-based compensation$661,000$762,000$1.11M$2.40M$2.66M

Free plan shows the latest 5 periods; Pro shows all 7 🔒

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-18 06:30.